CD40 and neoplasm: CD40 agonists (such as Selicrelumab) promote tumor antigen presentation and T cell activation by activating CD40 receptors on the surface of dendritic cells (Vonderheide, 2020), and form an “antigen release-presentation-response” closed loop when combined with gemcitabine.